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Background: This randomized, partially single-blinded, 6-period crossover clinical study of adult smokers compared
the nicotine pharmacokinetics, impacts on smoking urge and tolerability of various formulations of one brand of
e-cigarettes with that of a tobacco cigarette.
Methods: Five e-cigarettes with different e-liquid formulations containing 1.6 % and 2.4 % nicotine and a conventional
tobacco cigarette were randomized among 24 subjects under two exposure sessions consisting of a 30-min controlled
and a one-hour ad lib use period to assess plasma nicotine levels, impacts on smoking urge and adverse events. The
30-min controlled use session comprised an intensive use of the e-cigarettes with a total of 50 puffs taken every 30 s
for comparison to a single conventional cigarette having a typical machine-measured nicotine yield (~0.8 mg). Ad lib
product use conditions provided insight into more naturalistic product use behaviors and their accompanying smoking
urge reductions. Adverse events (AEs) were assessed by the Principal Investigator.
Results: Significant (p < 0.05) increases in plasma nicotine concentrations occurred within 10 min of controlled
e-cigarette use and significant (p < 0.001) reductions from baseline smoking urge were observed within 5 min.
E-cigarette and cigarette nicotine plasma levels were comparable for up to one hour of use. After both sessions
(90 min), nicotine exposure was the highest for the cigarette, with all e-cigarettes showing 23 % to 53 % lower
plasma concentrations. During controlled use, peak reduction in smoking urge for e-cigs occurred later than for
the cigarette. After completion of both sessions, significant smoking urge reduction persisted for most of the
tested e-cigarettes, albeit at levels lower than that provided by the tobacco cigarette. Nicotine content, vehicle
differences, and the presence of menthol did not significantly affect smoking urge reduction by the e-cigarettes.
No subjects were discontinued due to AEs. The most frequently reported AEs events included cough, throat
irritation, headache, and dizziness.
Conclusions: Blood plasma nicotine levels obtained from short-term use of e-cigarettes containing 1.6 % and
2.4 % nicotine were significant, but lower than those of conventional tobacco cigarettes, yet the reduction in
craving symptoms were broadly comparable. The types of AEs were consistent with other research studies of
longer duration that have reported that use of e-cigarettes by adult smokers is well-tolerated.
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Smoking remains the leading preventable cause of pre-
mature death in the United States [1]. Electronic ciga-
rettes (e-cigarettes) are rapidly becoming a popular
alternative to cigarette smoking worldwide and are
garnering significant attention as potentially reduced-
exposure replacements for conventional cigarettes (ciga-
rettes) [2–6]. E-cigarettes consist of a battery, heating
component, and a cartridge containing tobacco-derived
nicotine in a solution composed of glycerin and/or pro-
pylene glycol (PG), and flavorings. Upon activation, the
heating element heats the solution to generate an aero-
sol that is inhaled by the consumer in a manner that
mimics smoking.
Pharmacokinetic studies with early-generation e-
cigarettes found that they delivered markedly lower
levels of plasma nicotine than conventional cigarettes
[7, 8]. More recent studies have reported that experi-
enced subjects using later-generation e-cigarettes con-
taining 9 to 24 mg/mL of nicotine attain significant
increases in plasma nicotine concentrations over base-
line values that can be similar to those obtained from
conventional cigarette smoking [9–11]. These results
suggest that an acclimation to the product may be
necessary for naïve smokers to become familiar with
the characteristics of the specific e-cigarettes in order
to effectively use them in a subjectively enjoyable
manner. Moreover, these studies also demonstrated a
reduction in smoking urge or abstinence symptoms
following e-cigarette use, even for products that de-
liver less nicotine than conventional tobacco cigarettes.
This is quite consistent with a perspective that the substan-
tial sensory and behavioral aspects of cigarette smoking
that are mimicked by e-cigarettes may provide meaningful
relief of the cigarette cravings commonly reported by ab-
stinent smokers.
Surveys and clinical studies evaluating the impacts,
tolerability and adverse events (AEs) associated with
e-cigarette use suggest that they are generally well-
tolerated following short-term use [1, 9, 12–16].
Commonly reported AEs include symptoms such as
mouth and throat irritation, light-headedness, dizzi-
ness and dry cough.
The primary objective of this study was to examine
the nicotine blood plasma levels and smoking urge
impacts of various formulations of one brand of e-
cigarette with that of a tobacco cigarette. The tested
products contained different flavorings, aerosol form-
ing excipients (i.e., propylene glycol, glycerin) and
nicotine levels. The secondary objectives were to as-
sess the tolerability and any adverse events associated
with the study products following short-term use
under intensive controlled use conditions, as well as
under more natural ad-lib use conditions.Methods
Participants
The study protocol and the informed consent forms
were approved by Chesapeake IRB, Columbia, MD. A
total of 107 potential subjects were recruited from the
Lincoln, NE area using standard advertising methods
(i.e., print and radio advertisements) and from a database
of subjects who had previously participated a clinical
research study or who had expressed interest in participat-
ing in a study. All potential subjects were provided details
regarding the study and written informed consent was
obtained prior to completion of any study procedures.
Sixty-one subjects were excluded for not meeting the
predefined inclusion/exclusion criteria, while five sub-
jects declined to participate prior to enrollment and
three subjects were excluded because the study had
reached the recruitment target of 38 eligible subjects.
The 38 subjects meeting the eligibility criteria partici-
pated in a 7-day at-home lead-in period during which
they used and became familiar with two of e-cigarette
study products (non-menthol and menthol, 2.4 %
nicotine with glycerin). All subjects who participated
in the at-home lead-in period were allowed to check
in at the start of clinical conduct. Two subjects chose
not to participate further after the lead-in period and
one subject failed further screening requirements at
check-in. A final study population of 24 subjects were
enrolled into the study and randomized into one of
six product usage sequences with four subjects per
sequence. One subject withdrew consent after com-
pletion of the first product use on Day 1 of the trial
due to a personal reason (family emergency). All sub-
jects participating in the study from the time of the
lead-in period were paid for their participation.
The main criteria for inclusion were as follows: healthy
adult male and female smokers, 21 to 65 years of age,
inclusive; smoker for at least 12 months and currently
smoked an average of 10 or more manufactured ciga-
rettes per day (no restriction on brand-style); positive
urine cotinine at screening (≥ 500 ng/mL); and exhaled
carbon monoxide CO > 10 ppm at screening. Exclusion
criteria included: history or presence of clinically signifi-
cant mental or physical health conditions; females who
were pregnant or breastfeeding; high blood pressure;
body mass index < 18 kg/m2 or > 40 kg/m2; acute
illnesses (e.g., upper respiratory infection, viral infection)
requiring treatment within 2 weeks prior to check-in;
use of prescription smoking cessation treatments, anti-
diabetic or insulin drugs or medications known to inter-
act with cytochrome P450 2A6; positive urine screen for
alcohol or drugs of abuse; and self-reported puffers (i.e.,
smokers who draw smoke from the cigarette into the
mouth and throat but do not inhale). Subjects who had
used any tobacco- or nicotine-containing products other
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of in-clinic product use were also excluded.
Products tested
A rechargeable version of an e-cigarette that is currently
sold in retail outlets throughout the United States was
used in this study. The rechargeable e-cigarette consists
of a battery segment and a cartomizer segment compris-
ing the heating unit and a liquid reservoir which can be
separated from the battery for recharging or replacement
when the e-liquid is depleted. The battery operates at a
voltage of 3.7 volts (nominal) and the resistance of the
heating element is approximately 3 ohms. The max-
imum operating temperature is dependent on both the
state of reservoir fluid fill and on the manner of use and
was not recorded in this study.
Two commercial e-cigarette products that contained
16 mg/mL (1.6 %) USP grade nicotine were used in this
study. As well, three non-commercial products that con-
tained 24 mg/mL (2.4 %) USP grade nicotine were used
in this study to evaluate various product characteristics
considered important to further product development.
In addition to nicotine, the e-cigarettes used in this
study contained USP grade glycerin and/or propylene
glycol (as described below), distilled water (<20 %), citric
acid (<1.0 %) and natural or artificial flavors (<10 %).
The nicotine yield of the conventional cigarette used in
the study was approximately 0.8 mg per cigarette [17].
The study products included:
Product A: Classic Tobacco flavored e-cigarette
(2.4 % nicotine, ~75 % glycerin)
Product B: Classic Tobacco flavored e-cigarette
(2.4 % nicotine, ~50 % glycerin/~20 % propylene glycol)
Product C: Menthol flavored e-cigarette (2.4 %
nicotine, ~75 % glycerin)
Product D: Classic Tobacco flavored e-cigarette
(1.6 % nicotine, ~75 % glycerin)
Product E: Classic Tobacco flavored e-cigarette
(1.6 % nicotine, ~50 % glycerin/~20 % propylene glycol)
Product F: Tobacco Cigarette
Study design
This was a randomized, partially single-blinded, six-
period crossover study conducted at a single independ-
ent research center (Celerion, Lincoln, NE). Twenty-four
subjects were randomly selected from the pool of 38
subjects who participated in the at-home lead-in period
were enrolled into the testing phase of the trial and
randomized to assigned product sequences. The subjects
checked into the clinic on Day −2 and abstained from
using of nicotine-containing products until product use
on Day 1. Days 1, 3, 5, 7, 9, and 11 were designated
product use days while Days −1, 2, 4, 6, 8, and 10 weredesignated wash-out days. The subjects were housed at
the test site from the time of check-in through comple-
tion of study events on Day 11. The clinic staff moni-
tored the subjects during the confinement period to
ensure that no illicit nicotine or tobacco products were
used. Study investigators were not blinded, but the
subjects were as the all the e-cigarette products ap-
peared the same. The menthol product, however, was
easily discernible due to taste.
Previous studies have demonstrated that a lack of famil-
iarity with e-cigarette products may result in low nicotine
intake with their use [7, 18]. In order to allow study partic-
ipants to become familiar with the e-cigarette devices,
subjects were instructed on the appropriate use of the
products and were required to demonstrate the appropri-
ate use to clinic staff. Each subject was then provided with
two units of the menthol and non-menthol 2.4 % nicotine
products containing glycerin for at-home use prior to the
start of the study and instructed to use the products each
day during the 7-day lead-in period.
Two types of exposures were utilized in the study on
each product use day: a controlled use period followed
by an ad lib use period. Similar 2-stage designs have
been informative in prior studies evaluating the nicotine
delivery and subjective effects of e-cigarettes [5–9, 19].
Enrolled subjects were randomized into one of six
product usage sequences (Table 1) with four subjects
per sequence.
Given the wide variability in smoking behaviors, the
controlled use period of the study was intended to pro-
vide some degree of standardization of the nicotine
“dose” associated with each of the study products to bet-
ter understand potential influences of different vehicles,
flavor characteristics and nicotine content on measured
parameters. As such, the controlled use period of the
study consisted of 50 puffs of the assigned e-cigarette
product (5-s puffs at 30-s intervals, approximately
24.5 min of use) and smoking one conventional tobacco
cigarette (30-s intervals with the subjects’ normal puff
duration, approximately 4.5 min of use). Fifty e-cigarette
puffs was selected as an optimal controlled “dose” as it
approximated the dose of nicotine delivered by the
cigarette used in the study (~0.8 mg) based on machine
yields of the e-cigarettes determined previously using a
standardized Canadian Intense puffing protocol [20, 21].
Thus, this controlled “dose” period was intended to
reflect intensive usage of the e-cigarettes for comparison
to the tobacco cigarette used in the study. During the
controlled use period, subject puff counts were moni-
tored by the clinical staff and all e-cigarettes were
weighed before and after use in order determine the
amount of solution consumed.
Further, evaluation under the ad lib use conditions pro-
vided plasma nicotine levels under uncontrolled, natural
Table 1 Summary of study demographics and FTCD scores by study product sequence and overall
Trait/Test Category/Statistic Study product sequence
ABFCED (N = 4) BCADFE (N = 4) CDBEAF (N = 4) DECFBA (N = 4) EFDACB (N = 4) FAEBDC (N = 4) Overall (N = 24)
Sex Female 2 (50 %) 2 (50 %) 2 (50 %) 2 (50 %) 2 (50 %) 2 (50 %) 12 (50 %)




1 (25 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (4 %)
Black or African
American
0 (0 %) 1 (25 %) 0 (0 %) 2 (50 %) 0 (0 %) 0 (0 %) 3 (13 %)
White 3 (75 %) 3 (75 %) 4 (100 %) 2 (50 %) 4 (100 %) 4 (100 %) 20 (83 %)
Ethnicity Hispanic or Latino 1 (25 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (4 %)
Not Hispanic or Latino 3 (75 %) 4 (100 %) 4 (100 %) 4 (100 %) 4 (100 %) 4 (100 %) 23 (96 %)
Age (yrs) Mean 38.3 40.5 38.3 35.3 34.0 45.8 38.7
SD 12.04 15.70 15.44 4.03 9.49 6.13 10.77
Height (cm) Mean 167.25 175.75 168.75 172.75 167.00 171.75 170.54
SD 3.403 10.243 6.131 3.775 8.206 9.811 7.331
Weight (kg) Mean 84.1 79.2 70.8 74.7 80.0 83.9 78.8
SD 16.52 25.89 6.15 13.13 12.93 14.14 14.91
BMI (kg/m2) Mean 30.050 25.198 24.798 25.015 28.948 28.375 27.064






Mean 4.0 5.3 5.0 6.0 4.0 7.8 5.3
SD 2.16 0.5 1.41 2.16 2.16 2.63 2.18
Median 3.5 5.0 4.5 5.5 4.5 8.5 5.0
Minimum 2 5 4 4 1 4 1
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accompanied by subjective self-assessments of smoking
urge. During ad lib use, subjects assigned to an e-cigarette
or tobacco cigarette product were allowed to use the
product as desired for the entire hour (use of the assigned
e-cigarette products in an unrestricted manner or smok-
ing as many tobacco cigarettes as they chose) and subjects
were responsible for maintaining their own puff counts.
All e-cigarette products were weighed before and after
use. The ad lib use period was conducted immediately
following the end of the controlled product use session.
Blood samples for plasma nicotine determinations, smoking
urge assessments, blood pressure, pulse rate, and exhaled
CO measurements were also obtained at scheduled time
points on each product use day.
Pharmacokinetics (PK) - plasma nicotine
Blood samples for the measurement of plasma nicotine
concentrations were taken by direct venipuncture at
10 min prior to, and at 5, 10, 15, 20, 25, 30, 45, 60, 75, and
90 min following the start of the controlled product usage
on Days 1, 3, 5, 7, 9, and 11. Plasma nicotine was analyzed
by LC-MS/MS using validated analytical methods with
appropriate quality controls in accordance with applicable
FDA Good Laboratory Practice regulations (Title 21 CFR
Part 58). The limit of quantification for nicotine was
0.200 ng/mL.
The following PK parameters were calculated:
 Cmax0–30 - maximum observed concentration from
time zero to 30 min.
 AUC0–30 - area under the concentration-time curve
from time zero to 30 min.
 tmax0–30 - time of the maximum concentration from
time zero to 30 min.
 AUC30–90 - area under the concentration-time curve
from 30 to 90 min.
 C90 - maximum observed concentration at 90 min.
Pharmacodynamics – smoking urge
Smoking urge was assessed using a simple and subjective
100 mm visual analog scale (VAS). Various forms of
VAS have been used in e-cigarette studies as a tool for
obtaining various subjective effects data associated with
e-cigarette use and measuring nicotine and smoking ab-
stinence symptom suppression [6–10]. Participants were
asked to rate “how strong is your urge to smoke right
now?” by placing a line through a 100 mm line where far
left indicated: ‘not at all’ and far right indicated: ‘extremely’.
Assessments occurred within 1 min prior to the −10 (pre-
product use), 5, 15, 25, 30, 60, and 90-min PK blood draws.
The smoking urge change-from-baseline was calculated as
the difference between the pre-use and post-use smoking
urge result for each tested product.The following pharmacodynamic (PD) parameters were
calculated:
 Emax0–30 - Maximum smoking urge change-from-
baseline from time zero to 30 min.
 Emaxreduction0–30 - Maximum smoking urge
reduction from baseline from time zero to 30 min.
 AUEC0–30 - Area under the effect curve (smoking
urge change-from-baseline) from time zero to 30 min.
 tEmax0–30 - Time of the maximum smoking urge
change-from-baseline from time zero to 30 min.
 AUEC30–90 - Area under the effect curve (smoking
urge change-from-baseline) from 30 to 90 min.
 E90 - Observed smoking urge change-from-baseline
at 90 min.
Tolerability and Adverse Events (AEs)
Tolerability evaluations included assessments of AEs, vital
signs and concomitant medications. AEs reported by the
subjects or observed by the clinic staff were assessed for
severity (mild, moderate, or severe), as serious or not
serious, and relationship to the study products (unrelated,
unlikely, possible, probable, or definite) by the Principal
Investigator. A study product use-emergent AE was de-
fined as an AE that started or intensified at the time of or
after study product usage. An AE that occurred during the
washout period between study products was considered
study product use-emergent for the last study product
given. All reported AEs were coded with Medical
Dictionary for Regulatory Activities (MedDRA®), Ver-
sion 17.0. AEs were recorded by frequency by study
product and the number of subjects experiencing product
use-emergent AEs.
Data analyses
Non-compartmental PK and smoking urge parameters
were calculated using Phoenix® WinNonlin® Version 6.3
(Certara, Princeton, NJ) from the individual nicotine
concentration and smoking urge change-from-baseline
data. All statistical summarizations and comparisons were
calculated using SAS® Version 9.3 (SAS, Cary, NC). Ana-
lyses of variance were performed on the plasma nicotine
AUC0–30, AUC30–90, Cmax0–30, and C90 parameters, and a
Wilcoxon Signed Rank Test was used for the tmax0–30 par-
ameter to assess differences between the e-cigarettes and
the tobacco cigarette. Usual brand cigarette flavor (men-
thol or non-menthol) was included in each of the analyses
as a covariate to account for any impact that flavor prefer-
ence might have had on the results. Repeated measures
ANOVA with simple contrasts were used to compare the
maximum observed concentrations of plasma nicotine
within the first 30 min and at 90 min (Cmax0–30 and C90)
to the pre-product use concentration. The smoking urge
parameters AUEC0–30, AUEC30–90, Emax0–30, E90, and
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used in the PK analyses. Differences were considered sta-
tistically significant at an alpha level of 5 %.
Results and discussion
Participant characteristics
Of the 24 subjects who were enrolled into the testing
phase of the study and randomized to study product
sequences, 23 subjects completed the study and one sub-
ject withdrew due to a family emergency. A summary of
the subjects’ demographics together with the results of
the Fagerström Test for Cigarette Dependence (FTCD)
scores [22, 23] for all study participants by study product
sequence and overall is presented in Table 1.
Product use
The mean pre-to-post use product weight differences for
the e-cigarettes and the mean puffs taken from all prod-
ucts during each period of the study are provided in
Table 2. During controlled product administration, all
subjects were to take the same number of puffs (50) from
the e-cigarette products with a defined inhalation pattern
(5-s puffs every 30 s) while monitored by the clinical staff
in an attempt to standardize nicotine intake. The resulting
mean weight differences were comparable across study
products (0.2238 - 0.2570 g), with the highest and lowest
estimated nicotine delivery from the 1.6 % nicotine prod-
ucts. During the ad lib product use period, subjects were
free to puff as often as they chose with no limitation on
puff duration. As a result, the number of puffs from each





2.4 % nic + Gly 50.0 (50–51) 0.2251 ±
N = 23
2.4 % nic + Gly/PG 50.0 (50–51) 0.2349 ±
N = 23
2.4 % nic + Gly + menthol 50.0 (50–51) 0.2421 ±
N = 23
1.6 % nic + Gly 50.0 (50–51) 0.2238 ±
N = 23




Tobacco Cigarette 10.5 (9–13) 1.0 (NA
N = 24
Values for puff count and cigarettes smoked are presented as mean (range). Values
nic nicotine, Gly glycerine, PG propylene glycolduring the ad lib use period. However, the mean puff
counts were fairly comparable across products, averaging
between 49.5 and 60.3, with the highest and lowest mean
puff counts again noted with the 1.6 % nicotine products.
Product weight differences followed the same pattern.
Hence, there was no clear indication in either period that
subjects compensated during use of the lower nicotine-
containing products by taking more or deeper puffs in an
attempt to self-administer more nicotine.
The mean differences in product weights were observed
to be smaller for each e-cigarette (~22 % - 54 %) following
ad lib product use compared to the controlled product
administration despite the subjects having taken similar
numbers of puffs, or more, during ad lib product use. This
was likely due to shorter puff durations during ad lib
product use.
For the tobacco cigarettes, subjects smoked only a single
cigarette during the controlled product administration,
with an average of 10.5 puffs per cigarette taken. During
the ad lib phase subjects smoked an average of 3.6 ciga-
rettes, with approximately the same number of puffs taken
per cigarette.
Nicotine pharmacokinetics and blood plasma levels
The mean plasma nicotine concentration-time profiles are
presented in Fig. 1. Baseline nicotine concentrations were
below the limit of quantification in the majority of sub-
jects and mean baseline nicotine concentrations were
comparable across study products, all representing less
than half the limit of quantification of 0.200 ng/mL.






0.0408 52.3 (5–128) 0.1467 ± 0.0843
0.0633 55.4 (4–136) 0.1445 ± 0.0880
0.0477 58.0 (8–140) 0.1604 ± 0.0827
0.0399 60.3 (8–112) 0.1738 ± 0.0937
0.0433 49.5 (3–118) 0.1194 ± 0.0675
es Puffs Cigarettes
Smoked
) 38.6 (16–103) 3.6 (2–7)
for the pre-to-post weight differences are presented as mean ± SD
Fig. 1 Mean Plasma Nicotine Concentration Versus Time
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tobacco cigarette (p < 0.05 compared to baseline) and then
steadily decreased until reaching a minimum at the end of
the period. For all e-cigarettes, nicotine plasma absorption
was slower, with mean concentrations steadily increasing
with continued product use and peaking at the end of the
period. Usage of the study e-cigarettes resulted in statisti-
cally significant (p < 0.05) increases from baseline in nico-
tine concentration as soon as 5 min following the start of
product use with the exception of the 1.6 % nicotine prod-
uct with glycerin, which also reached statistical signifi-










N = 23 N = 23 N = 2
Cmax0–30 (ng/mL) 17.4 ± 5.97 18.1 ± 6.47 15.3 ±
p-value 0.1242 0.0508 0.885
Tmax0–30 (hr) 0.50 (0.33, 0.55) 0.50 (0.33, 0.52) 0.50 (
p-value <0.0001 <0.0001 <0.00
AUC0–30 (ng*hr/mL) 4.7 ± 1.84 4.9 ± 1.75 4.1 ±
p-value 0.7636 0.8443 0.040
AUC30–90 (ng*hr/mL) 22.4 ± 5.61 24.6 ± 7.99 21.6 ±
p-value 0.8463 0.0602 0.631
C90 (ng/mL) 19.7 ± 5.72 22.4 ± 7.65 19.4 ±
p-value <0.0001 <0.0001 <0.00
Tmax0–30 is presented as median (minimum, maximum), all other values are presente
in least squares means between groups. P-values represent the comparison to the t
nic nicotine, Gly glycerine, PG propylene glycolsteadily increased during the one-hour ad lib use of the
tobacco cigarettes, whereas ad lib use of the e-cigarettes
resulted in plasma nicotine concentrations that increased
during the first 45 min and then plateaued during the last
15 min.
The summary of nicotine plasma PK parameters is
presented in Table 3. The controlled e-cigarette puffing
regimen provided peak (Cmax30) and overall (AUC0-30)
nicotine exposures comparable to the tobacco cigarette
for the two non-menthol 2.4 % nicotine products and
the 1.6 % nicotine product containing glycerin and PG









3 N = 23 N = 23 N = 24
5.16 10.3 ± 3.70* 15.1 ± 4.61 15.8 ± 8.64
8 0.0002 0.7776
0.33, 0.52) 0.50 (0.33, 0.61) 0.50 (0.33, 0.62) 0.09
(0.08, 0.42)
01 <0.0001 <0.0001
1.63 3.0 ± 1.18 4.3 ± 1.39 4.9 ± 1.79
6 <0.0001 0.0928
5.08 14.7 ± 5.15 19.8 ± 4.72 22.1 ± 5.98
9 <0.0001 0.0756
5.80 13.7 ± 5.98 16.8 ± 4.44 29.2 ± 10.86
01 <0.0001 <0.0001
d as arithmetic mean ± SD. Statistical significance is based on the differences
obacco cigarette
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glycerin provided significantly lower peak (35 %) and over-
all (39 %) exposures despite having the highest mean puff
counts of any of the e-cigarette products. Use of the men-
thol product (2.4 % nicotine with glycerin) also yielded a
significantly lower overall exposure (16 %) compared to
the tobacco cigarette, but a comparable peak concentra-
tion. Not surprisingly, the use pattern of the e-cigarette
during the controlled use period resulted in a significantly
longer time to peak nicotine concentration (Tmax0–30)
than for the single tobacco cigarette.
During the ad lib use period, overall nicotine exposure
(AUC30–90) was comparable (differences within 11 %)
between the tobacco cigarette and all e-cigarette products
with the exception of the 1.6 % nicotine product with only
glycerin, which provided a 33 % lower overall exposure.
However, the nicotine concentration at the end of the ad
lib use period was significantly higher following use of the
tobacco cigarette compared to the e-cigarettes, with con-
centrations ranging from 23 % to 53 % lower after 60 min
of ad lib use.
Overall, the exposure parameters among the e-cigarette
products tended to be higher for the 2.4 % nicotine prod-
ucts, higher for the products containing both glycerin and
PG, and lower for the product containing menthol com-
pared to the other 2.4 % nicotine products.Pharmacodynamics: effects on urge to smoke
The mean smoking urge change from baseline-time pro-
files are presented in Fig. 2. Mean baseline smoking urge
values across all test products were comparable, with the
mean visual assessment scale (VAS) responses ranging
from 62 to 68 out of 100 (mm).Fig. 2 Mean Smoking Urge Change from Baseline versus Time (Note: MoreAn immediate statistically significant (p < 0.001) reduc-
tion in smoking urge was observed at 5 min following
the start of controlled use of each study product. Follow-
ing use of a single tobacco cigarette, the maximum
reduction in smoking urge was observed at 5 min, ap-
proximately corresponding to the end of use of that
study product, and then increased during the remainder
of the controlled use period. Continuous use of the e-
cigarette products throughout the controlled use period
resulted in a maximal reduction in smoking urge also
approximately corresponding to the end of product use.
During the ad lib use period, use of the tobacco
cigarette resulted in a steady decrease in smoking urge,
peaking at the final time point, while the response with
the e-cigarettes peaked 30 min into ad lib use and stabi-
lized during the final 30 min.
Table 4 summarizes the change in smoking urge PD
parameters. No statistically significant differences were
found in the maximal smoking urge reduction parame-
ters Emax0–30 and Emaxreduction0–30 (all differences within
11 %) or the overall smoking urge reduction parameter
AUEC0-30 (all differences within 21 %) between the use
of a single tobacco cigarette and each of the e-cigarettes
during the controlled use period. The mean time to the
maximal reduction in smoking urge was shorter for the
tobacco cigarette (15 min) than each of the e-cigarettes
(25 – 30 min), but only significantly so for both of the
1.6 % nicotine products and the 2.4 % nicotine product
with menthol.
During the ad lib use period, the overall smoking urge
reduction (AUEC30-90) achieved with use of the e-cigarettes
were comparable to that of the tobacco cigarette, with all
differences less than 10 %. However, at the end of the ad lib
period, use of the tobacco cigarette resulted in a 19 % toNegative Values Indicate a Stronger Urge Reduction)




2.4 % nic + Gly 2.4 % nic + Gly/PG 2.4 % nic + Gly +menthol 1.6 % nic + Gly 1.6 % nic + Gly/PG Tobacco Cigarette
N = 23 N = 23 N = 23 N = 23 N = 23 N = 24
Emax0–30 (mm) −41.9 ± 26.56 −44.7 ± 26.98 −37.0 ± 30.25 −40.2 ± 32.47 −40.7 ± 24.25 −41.5 ± 27.43
p-value 0.9285 0.6427 0.3023 0.6972 0.7450
Emaxreduction0–30 (mm) −42.2 ± 26.01 −44.7 ± 26.98 −39.1 ± 25.86 −41.4 ± 30.40 −40.7 ± 24.25 −41.7 ± 27.08
p-value 0.9489 0.6505 0.5056 0.8480 0.7079
AUEC0–30 (hr*mm) −14.1 ± 10.56 −15.5 ± 10.39 −12.2 ± 10.75 −13.9 ± 12.09 −13.3 ± 8.29 −15.4 ± 12.67
p-value 0.4054 0.8912 0.0882 0.3590 0.2225
TEmax0–30 (hr) 0.41 (0.07, 0.50) 0.41 (0.07, 0.50) 0.41 (0.08, 0.50) 0.42 (0.08, 0.50) 0.49 (0.24, 0.50) 0.25 (0.07, 0.51)
p-value 0.1764 0.0948 0.0014 0.0012 0.0009
AUEC30–90 (hr*mm) −44.3 ± 35.39 −50.9 ± 33.64 −42.7 ± 38.24 −46.2 ± 40.23 −47.7 ± 34.16 −46.9 ± 30.14
p-value 0.6679 0.5275 0.5046 0.8919 0.9395
E90 (mm) −37.0 ± 30.69 −42.5 ± 29.85 −34.3 ± 34.03 −37.4 ± 35.08 −38.5 ± 30.12 −52.2 ± 26.33
p-value 0.0060 0.0921 0.0010 0.0066 0.0122
TEmax0–30 is presented as median (minimum, maximum), all other values are presented as arithmetic mean ± SD. Statistical significance is based on the differences
in least squares means between groups. P-values represent the comparison to the tobacco cigarette
nic nicotine, Gly glycerine, PG propylene glycol
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to the e-cigarettes, with statistically significant differences
for all except the 2.4 % nicotine product containing both
glycerin and PG.
The smoking urge reduction appeared comparable
among the e-cigarette products with the exception of
the 2.4 % nicotine product with menthol which tended
to provide a somewhat lower level of relief compared to
the other four products.
Tolerability and reported adverse events
During the course of the study, a total of 38 subjects
were exposed to one or more of the study products.
There were no serious adverse events reported and no
subjects were discontinued due to AEs. Mild product-
use-emergent AEs were reported by 18 of 38 subjects
provided a study product (including the lead-in period).
The number of subjects reporting AEs was similar
among products, ranging from 3 to 10 subjects each,
with slightly fewer subjects experiencing AEs following
use of the menthol-flavored product. The most frequent
AE was cough, reported 20 times by 11 subjects (more
commonly with use of an e-cigarette product than the
tobacco cigarette), followed by throat irritation (8
reports by 5 subjects) and headache (6 reports by 5 sub-
jects), and dizziness (5 reports by 4 subjects). All AEs
resolved without sequelae.
The observed acute effects of the study products on
blood pressure, heart rate and CO levels were previously
reported by the authors under a separate publication
[24] where it was noted that heart rate and systolic and
diastolic blood pressure were significantly elevated afterthe use of the tobacco cigarette, but the elevation was
less after use of most of the e-cigarettes. Furthermore, it
was also observed that the use of the e-cigarettes pro-
duced no increase the exhaled CO levels, whereas the
cigarette significantly increased the exhaled CO more
than eight (8) times above the baseline.
Conclusions
The key objectives of this study were to examine the
nicotine blood plasma levels and smoking urge impacts
of various formulations of one brand of e-cigarette for
comparison to a conventional tobacco cigarette, and to
assess the tolerability and adverse events associated with
the study products following short-term use under in-
tensive and naturalistic use conditions. The study design
and results are not intended to support the potential for
e-cigarettes as harm-reduction products.
While not all puffing parameters can be controlled across
all subjects, a product use that includes the same number
of puffs, puff duration, and puff interval as utilized in this
study allows for standardization of nicotine intake to the
extent possible in order to accurately characterize uptake
and reduction in smoking urge. The small difference in
pre-to-post use weight differences across the e-cigarette
products supports this. When compared to a tobacco
cigarette, the nicotine PK following a controlled, 50-puff
use of the e-cigarettes was characterized by slower absorp-
tion than from a single tobacco cigarette, but comparable
maximal and overall nicotine exposures for all but the
1.6 % nicotine product with glycerin. Analysis of the mean
maximum plasma concentrations attained during the
controlled use period showed that the non-menthol
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of the tobacco cigarette (15.8 ng/mL at approximately
5 min) with approximately 25 min of use (17.8 to 18.1 ng/
mL). This observation is most likely attributable to the ra-
ther intensive e-cigarette puffing regimen (one puff every
30 s) imposed during the controlled use interval when
compared to the single tobacco cigarette regimen (average
10.5 puffs total). However, it also suggests that under an
intensive puffing scenario, e-cigarettes are capable of de-
livering similar amounts of nicotine as a tobacco cigarette.
The continuous rise in nicotine concentrations achieved
with use of the e-cigarettes during the controlled use
period appeared to be matched by a consistent decrease in
smoking urge, though at the end of the 30-min controlled
use period the urge reduction was comparable across
those products. Smoking a single cigarette during the
controlled use period produced a predictable nicotine
concentration-time curve, with a rapid peak nicotine con-
centration followed by a gradual elimination. The rise and
fall of nicotine concentration was matched by the smoking
urge response, with a rapid decrease in urge followed by a
gradual return toward baseline. While the time to max-
imum urge reductions was significantly shorter for the
tobacco cigarette during the controlled use period com-
pared to each of the e-cigarettes, there were no significant
differences in the maximal or overall urge reduction
achieved between the two types of products.
Ad lib use of the study products can provide insight
into use patterns and nicotine concentrations that will
allow consumers to satisfy their smoking urge and pro-
vide an overall satisfying product use experience. As
should be expected, individual use of the products as
measured by puff counts varied widely and followed the
amount of nicotine solution that was consumed during
use as measured by pre-to-post use product weight dif-
ference. Use of the e-cigarettes during the ad lib use
period resulted in a relatively small increase in nicotine
concentration during the first 45 min, followed by a plat-
eau during the last 15 min. In contrast, use of the
cigarette during the ad lib use period resulted in a
continuous increase in nicotine concentration and con-
tinued reduction in smoking urge through the final time
point.
Following ad lib use of all products for 60 min, the
tobacco cigarette yielded a significantly higher nicotine
concentration (C90) compared to each of the e-cigarettes.
The higher nicotine concentration coincided with a
greater reduction in smoking urge at the end of the ad lib
use period (E90) for the tobacco cigarette compared to all
e-cigarettes, and significantly greater than all except the
2.4 % nicotine product containing glycerin and PG. How-
ever, there was no overall impact on urge as assessed by
AUEC30–90. This was likely due to the relatively short dur-
ation of the ad lib use. Indeed, as the smoking urgeresponse appeared to have reached a plateau with the e-
cigarettes and continued to increase with the cigarette
following 60 min of ad lib use, a longer evaluation period
may have resulted in a difference in the AUEC parameter
as well.
Among the e-cigarettes, use of the e-cigarettes con-
taining 1.6 % nicotine resulted in lower nicotine expos-
ure compared to the e-cigarettes containing 2.4 %
nicotine. However, this did not translate into significant
differences in the smoking urge response. Further, while
the suppression of urge to smoke appeared comparable
between the 1.6 % and the 2.4 % test formulations in the
present study, evaluation of the mean puff counts and
the amount of solution consumed did not suggest that
the subjects compensated by puffing on the lower-
nicotine products consciously or subconsciously more so
than the higher-nicotine products to achieve a similar
level of satisfaction. In addition, higher nicotine content,
the presence of PG in the vehicle, and the absence of
menthol in the e-cigarettes were found to increase
plasma nicotine levels during both controlled and ad lib
use. Such factors, however, did not appear to signifi-
cantly affect smoking urge. However, consistent with
prior research documenting the prominent role of condi-
tioned behavior and nicotine addiction, in addition to the
concentration of nicotine, the respiratory tract sensory
cues and manipulation of smoking materials that are asso-
ciated with smoking, and mimicked by e-cigarettes, may
have had a role in relieving smoking urges [25]. Thus, the
present findings further suggest that some of the substan-
tial sensory and behavioral aspects of smoking that are
mirrored by e-cigarettes, may be essential elements in the
reduction of craving or abstinence symptoms. To the
extent that e-cigarettes may provide some measure of
reduction in smoking urges, they may serve as cigarette
substitutes for smokers who would otherwise seek to
smoke a conventional tobacco cigarette.
Despite the aggressive puff regime employed in the
controlled use period, there were no SAEs in this study
and no subjects were discontinued due to AEs. The inci-
dence of AEs was similar among products, with slightly
fewer subjects experiencing AEs following use of the
menthol-flavored product. The most frequently reported
minor AEs were cough, followed by throat irritation,
headache, and dizziness. These findings are consistent
with other research studies of longer duration that have
reported that use of e-cigarettes by adult smokers is well-
tolerated as compared to tobacco cigarette use [2, 26].
This study was not without limitations. It was per-
formed at a single site with a small number of subjects,
which might lead to the conclusion that the data is not
generalizable to a broader population. However, many ini-
tial PK evaluations of tobacco and pharmaceutical prod-
ucts are performed using a similar approach. Further, the
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product use and a short-term ad lib product use to a sin-
gle brand of tobacco cigarette. Indeed, the trend we noted
at the end of the ad lib use period did show that nicotine
concentrations appeared to be continuing to rise and
smoking urge appeared to be continuing to decrease.
Hence, a longer term comparison in future studies would
be beneficial. Finally, while the product use data did not
provide a clear indication that subjects compensated by
using the products with less nicotine more intensively, use
of topography measurements providing insight into puff
volume and inhalation rate coupled with product evalu-
ation questionnaires in future studies might lend add-
itional information regarding product use behaviors
leading to PK and smoking urge responses.
Overall, the findings of this study indicate that nicotine
uptake from short-term use of e-cigarettes containing
1.6 % and 2.4 % nicotine are significant, but lower than
those of tobacco cigarettes, yet the reduction in urge-to-
smoke or craving symptoms are broadly comparable.
Moreover, it was also found that the short-term use of e-
cigarettes by adult smokers is well-tolerated as compared
to tobacco cigarette use.
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